Monopar Therapeutics (NASDAQ:MNPR) Upgraded by Zacks Research to “Strong-Buy” Rating

Zacks Research upgraded shares of Monopar Therapeutics (NASDAQ:MNPR) from a hold rating to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports.

A number of other equities analysts have also recently commented on the stock. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. UBS Group set a $105.00 price objective on shares of Monopar Therapeutics in a research report on Monday, June 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $105.00 target price on shares of Monopar Therapeutics in a report on Monday, June 29th. Three research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $108.75.

Monopar Therapeutics Stock Down 3.4%

Shares of NASDAQ MNPR opened at $99.79 on Monday. The business has a 50-day moving average price of $72.95 and a 200 day moving average price of $64.26. The stock has a market cap of $668.59 million, a PE ratio of -52.52 and a beta of 1.46. Monopar Therapeutics has a 52-week low of $29.18 and a 52-week high of $112.57.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.41. Sell-side analysts anticipate that Monopar Therapeutics will post -2.82 earnings per share for the current year.

Institutional Trading of Monopar Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. acquired a new stake in Monopar Therapeutics in the first quarter valued at about $673,000. Jane Street Group LLC purchased a new position in shares of Monopar Therapeutics during the 1st quarter worth approximately $377,000. Geode Capital Management LLC lifted its holdings in shares of Monopar Therapeutics by 99.7% in the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after buying an additional 48,379 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares in the last quarter. Finally, Rhumbline Advisers acquired a new position in Monopar Therapeutics during the second quarter worth $209,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.